The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

Investing.com - Shares in Eli Lilly (NYSE: LLY) sank by over 12% in premarket U.S. trading on Thursday after a study showed that the pharmaceutical giant’s weight-loss pill cut body weight by less ...

Eli Lilly stock falls after new data on its weight-loss drug Orforglipron, ahead of scheduled second-quarter earnings.

Trump’s tariffs, including new levies that took effect Thursday, are affecting global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.